Compare FFWM & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFWM | ARCT |
|---|---|---|
| Founded | 1990 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 521.3M | 194.1M |
| IPO Year | 2014 | N/A |
| Metric | FFWM | ARCT |
|---|---|---|
| Price | $6.18 | $6.39 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | $6.17 | ★ $38.67 |
| AVG Volume (30 Days) | 642.6K | ★ 786.5K |
| Earning Date | 01-29-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $159,621,000.00 | $97,601,000.00 |
| Revenue This Year | $166.48 | N/A |
| Revenue Next Year | $6.86 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 47.55 | N/A |
| 52 Week Low | $4.42 | $5.85 |
| 52 Week High | $6.47 | $24.17 |
| Indicator | FFWM | ARCT |
|---|---|---|
| Relative Strength Index (RSI) | 66.37 | 36.98 |
| Support Level | $6.00 | $6.38 |
| Resistance Level | $6.41 | $6.75 |
| Average True Range (ATR) | 0.18 | 0.41 |
| MACD | 0.03 | 0.17 |
| Stochastic Oscillator | 78.84 | 17.62 |
First Foundation Inc is a financial services company. It is engaged in providing investment management and financial planning services for high-net-worth individuals, retirement plans, charitable institutions, and private foundations. The company focuses on segments namely Banking and Wealth Management. It also offers loans to individuals and entities that own and operate multifamily residential and commercial real estate properties as well as business banking products and services to small to moderate-sized businesses, professional firms, and consumer banking products and services to individuals.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases. It operates in one business segment, which includes all activities related to the discovery, development, and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC and LUNAR-CF. Its Vaccine candidates include LUNAR-FLU, KOSTAIVE XBB.1.5, KOSTAIVE, and Others.